Taysha Gene Therapies, Inc. TSHA 深 沪
交易中 01-28 11:02:03 美东时间
4.535
-0.225
-4.73%
华盛通- 最 高4.77
- 今 开4.74
- 成交量 146.21万股
- 最 低 4.43
- 昨 收 4.76
- 总市值 12.43亿
- 52周最高 6.02
- 市盈率 静 --
- 换手率 0.53%
- 52周最低 1.05
- 委 比 45.10%
- 总股本 2.74亿
- 历史最高 33.35
- 量 比 3.08
- 振 幅 7.14%
- 历史最低 0.50
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Taysha Gene Therapies Advances TSHA‑102 Rett Syndrome Program; First Patient Dosed In REVEAL Pivotal Trial, FDA Alignment On ASPIRE Safety Data For Broad BLA, Dosing Completion Expected Q2 2026 With Longer‑Term Data Update In H1 2026
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sitesReached written alignment with FDA on inclusion of ≥3 months of
01-06 21:12
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Taysha Gene Therapies reports progress in the TSHA-102 pivotal program for Rett syndrome. First patient dosed in the REVEAL trial (Q4 2025), with enrollment ongoing across multiple sites. Written alignment with FDA to include ≥3 months of ASPIRE trial safety data in BLA submission for a broad label in patients ≥2 years. Dosing completion in REVEAL and ASPIRE trials expected Q2 2026, with long-term data update from REVEAL Part A in H1 2026. TSHA-1...
01-06 13:00
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标
杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-24 17:33
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies授予两名新员工总计212,000股股票期权，作为加入公司的激励，期权授予日期为2025年12月3日，行权价为每股4.49美元，有效期10年，分4年归属，第一年归属25%，剩余75%按月归属，归属条件为持续服务。
2025-12-05 21:05
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.
2025-11-05 20:40
Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year.
2025-11-04 19:58
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
2025-10-22 10:10
